Sponsored by: Diagnostica Stago, Inc. In clinical laboratory settings, coagulation factor tests are routinely conducted to identify inherited or acquired deficiencies in patients suspected of an ...

The indications, pharmacokinetics, and therapeutic guidelines for available coagulation products are reviewed. Patients with hemophilia, von Wille-brand's disease (VWD), or acquired inhibitors to ...

All that most laymen know about hemophilia is that it is an odd and dangerous disease of the blood that strikes men only, although it is transmitted by women. Medical researchers have learned a great ...

A novel gene therapy for hemophilia A led to sustained expression of the clotting factor those patients lack, resulting in a reduction—or in some cases complete elimination—of painful and potentially ...

Hemophilia B, also known as Christmas disease, is a bleeding disorder. Its characteristic feature is a deficiency of clotting factor IX. This is a protein present in the blood that helps with ...

Blood coagulation factor XIII (FXIII) is the final transglutaminase in the clotting cascade, responsible for cross-linking fibrin polymers and stabilising the haemostatic plug. In plasma it circulates ...

The phase 3 trial of valoctocogene roxaparvovec for severe hemophilia A showed it reduced bleeding events as well as the use of factor VIII concentrates. A phase 3 trial of valoctocogene roxaparvovec, ...

Hemophilia C is a rare, inherited blood disorder due to a deficiency of blood clotting protein Factor XI. It’s less severe than hemophilia A and B and is inherited differently. Still, it can cause ...

The European Medicines Agency (EMA) this week recommended granting a marketing authorization for Altuvoct (efanesoctocog alfa) for the treatment and prophylaxis of bleeding in patients with hemophilia ...